1.Dubin IN, Johnson FB. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore) 1954;33:155–197.
2.Shani M, Seligsohn U, Gilon E, Sheba C, Adam A. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med 1970;39:549–567.
3.Togawa T, Mizuochi T, Sugiura T, Kusano H, Tanikawa K, Sasaki T, Ichinose F, et al. Clinical, Pathologic, and Genetic Features of Neonatal Dubin-Johnson Syndrome: A Multicenter Study in Japan. J Pediatr 2018. 10.1016/j.jpeds.2017.12.058.
4.Keppler D. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos 2014;42:561–565.
5.Gazzin S, Masutti F, Vitek L, Tiribelli C. The molecular basis of jaundice: An old symptom revisited. Liver Int 2017;37:1094–1102.
6.Hashimoto K, Uchiumi T, Konno T, Ebihara T, Nakamura T, Wada M, Sakisaka S, et al. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 2002;36:1236–1245.
7.Wu L, Zhang W, Jia S, Zhao X, Zhou D, Xu A, Duan W, et al. Mutation analysis of the ABCC2 gene in Chinese patients with Dubin‑Johnson syndrome. Experimental and Therapeutic Medicine 2018; 16:4201–4206.
8.Zhang W, Xu A, Li Y, Zhao S, Zhou D, Wu L, Zhang B, et al. A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China. Liver international 2019;39:1120–1127.
9.Lv T, Zhang W, Xu A, Li Y, Zhou D, Zhang B, Li X, et al. Non- mutations in haemochromatosis in China: combination of heterozygous mutations involving signal peptide variants. Journal of medical genetics 2018;55:650–660.
10.Terlouw SA, Masereeuw R, van den Broek PH, Notenboom S, Russel FG. Role of multidrug resistance protein 2 (MRP2) in glutathione-bimane efflux from Caco–2 and rat renal proximal tubule cells. British journal of pharmacology 2001;134:931–938.
11.Park SW, Jun CH, Choi SK, Kim HJ, Kim GE. Hepatobiliary and Pancreatic: A black liver of Dubin-Johnson syndrome. J Gastroenterol Hepatol 2018;33:562.
12.Gilibili RR, Chatterjee S, Bagul P, Mosure KW, Murali BV, Mariappan TT, Mandlekar S, et al. Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay. Drug Metab Dispos 2017;45:604–611.
13.Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology 2014;146:1625–1638.
14.Cheng JB, Jacquemin E, Gerhardt M, Nazer H, Cresteil D, Heubi JE, Setchell KDR, et al. Molecular Genetics of 3β-Hydroxy-Δ5-C27-Steroid Oxidoreductase Deficiency in 16 Patients with Loss of Bile Acid Synthesis and Liver Disease. The Journal of Clinical Endocrinology & Metabolism 2003;88:1833–1841.
15.Huang HY, Zhou H, Wang H, Chen YX, Fang F. Novel Mutations in the 3β-hydroxy-Δ5-C27-steroid Dehydrogenase Gene (HSD3B7) in a Patient with Neonatal Cholestasis. Chinese Medical Journal 2016;129:98–100.
16.Bossi G, Giordano G, Rispoli GA, Maggiore G, Naturale M, Marchetti D, Iascone M. Atypical clinical presentation and successful treatment with oral cholic acid of a child with defective bile acid synthesis due to a novel mutation in the gene. Pediatric reports 2017;9:7266.
17.Wen X, Joy MS, Aleksunes LM. In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants. Pharm Res 2017;34:1637–1647.
18.Uchiumi T, Tanamachi H, Kuchiwaki K, Kajita M, Matsumoto S, Yagi M, Kanki T, et al. Mutation and functional analysis of ABCC2/multidrug resistance protein 2 in a Japanese patient with Dubin-Johnson syndrome. Hepatol Res 2013;43:569–575.
19.Keppler D. Progress in the Molecular Characterization of Hepatobiliary Transporters. Dig Dis 2017;35:197–202.